651719-20-9

Basic information

• Product Name: (S)-2-{(S)-2-[(S)-2-{(S)-2-[(S)-3-(4-tert-Butoxy-phenyl)-2-pent-4-enoylamino-propionylamino]-3-methyl-butyrylamino}-3-(trityl-carbamoyl)-propionylamino]-3-methyl-butyrylamino}-pent-4-enoic acid methyl ester
• Synonyms: (S)-2-{(S)-2-[(S)-2-{(S)-2-[(S)-3-(4-tert-Butoxy-phenyl)-2-pent-4-enoylamino-propionylamino]-3-methyl-butyrylamino}-3-(trityl-carbamoyl)-propionylamino]-3-methyl-butyrylamino}-pent-4-enoic acid methyl ester
• CAS NO: 651719-20-9
• Molecular Weight: 985.233
• Mol File: 651719-20-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-2-{(S)-2-[(S)-2-{(S)-2-[(S)-3-(4-tert-Butoxy-phenyl)-2-pent-4-enoylamino-propionylamino]-3-methyl-butyrylamino}-3-(trityl-carbamoyl)-propionylamino]-3-methyl-butyrylamino}-pent-4-enoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-{(S)-2-[(S)-2-{(S)-2-[(S)-3-(4-tert-Butoxy-phenyl)-2-pent-4-enoylamino-propionylamino]-3-methyl-butyrylamino}-3-(trityl-carbamoyl)-propionylamino]-3-methyl-butyrylamino}-pent-4-enoic acid methyl ester(651719-20-9)
• EPA Substance Registry System: (S)-2-{(S)-2-[(S)-2-{(S)-2-[(S)-3-(4-tert-Butoxy-phenyl)-2-pent-4-enoylamino-propionylamino]-3-methyl-butyrylamino}-3-(trityl-carbamoyl)-propionylamino]-3-methyl-butyrylamino}-pent-4-enoic acid methyl ester(651719-20-9)

Safety Data

• Hazardous Substances Data: 651719-20-9(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 68858-20-8 Fmoc-Val-OH 
• 71989-38-3 Fmoc-Tyr(tBu)-OH 
• 132388-59-1 L-Asn(Trt) 
• 146549-21-5 2-(9H-fluoren-9-ylmethoxycarbonylamino)-pent-4-enoic acid 

Downstream Products

• 651719-22-1 (Z)-(2S,5S,8S,11S,14S)-2-(4-tert-Butoxy-benzyl)-5,11-diisopropyl-3,6,9,12,20-pentaoxo-8-[(trityl-carbamoyl)-methyl]-1,4,7,10,13-pentaaza-cycloicos-16-ene-14-carboxylic acid methyl ester 

Relevant articles and documents

Cyclic phosphopeptides for interference with Grb2 SH2 domain signal transduction prepared by ring-closing metathesis and phosphorylation

Cyclic phosphopeptides were prepared using ring-closing metathesis followed by phosphopeptides. These cyclic phosphopeptides were designed to interact with the SH2 domain of Grb2, which is a signal transduction protein of importance as a target for antiproliferative drug development. Binding of these peptides to the Grb2 SH2 domain was evaluated by a surface plasmon resonance assay. High affinity binding to the Grb2 SH2 domain was maintained upon macrocyclization, thus indicating that this method can be used to assemble high affinity cyclic phosphopeptides that interfere with signal transduction cascades.